Products
Regadenoson is commercially available as a solution for injection (Rapiscan). It was approved in the United States in 2008, in the EU in 2010, and in many countries in 2017.
Structure and properties
Regadenoson (C15H18N8O5, Mr = 390.4 g/mol) is present in the drug as a monohydrate. It is a derivative of adenosine.
Effects
Regadenoson (ATC C01EB21) has vasodilator properties. It causes coronary vasodilation and increases coronary blood flow. The effects are due to agonism at the A2A adenosine receptor.
Indications
As a diagnostic agent in place of stress exercise for myocardial perfusion imaging with radionuclides in adult patients with insufficient exercise capacity.
Dosage
According to the SmPC. The drug is injected intravenously.
Contraindications
- Hypersensitivity
- Second- or third-degree AV block or sinus node dysfunction, unless these patients have a functioning pacemaker.
- Unstable angina that has not been stabilized with medication.
- Severe hypotension
- Decompensated stages of heart failure
For complete precautions and interactions, see the drug label.
Adverse effects
The most common potential adverse effects include respiratory disturbances, headache, flushing, chest pain, ST-segment changes on ECG, gastrointestinal disturbances, and dizziness.
